{"schema_version":"1.0","type":"article","title":"AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy","url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.md","lang":"en","date":"2026-07-31","publish_at":"2026-07-31T08:00:00+08:00","updated_at":"2026-07-31","category":"商業分析系列","topic":"商業分析系列","tags":["AnBogen Therapeutics","ABT-301","Cancer Immunotherapy","PD-1","Metastatic Colorectal Cancer","HDAC","Taiwan Biotech","Oncology"],"summary":"Can a small molecule from Taiwan extend the $30 billion PD-1 ecosystem into the 95% of metastatic colorectal cancer patients still beyond immunotherapy’s reach?","key_points":[],"facts":[],"sections":["01 | PD-1 Is a Blockbuster Success—But Much of the Market Still Has No Signal","02 | How ABT-301 Could Reconnect a Cold Tumor?","03 | Triple Therapy: Reprogram the Environment, Open the Vasculature, Release the Brakes","04 | The Same Path Has Already Produced a Human Signal","05 | The First Market Is $9 Billion. The Real Upside Is the “Constellation Effect”","06 | The Second Starlink Node: ABT-500 Connects Diagnosis, Patient Selection, and Therapy","07 | Four Signal Upgrades Will Determine AnBogen’s Next Valuation Step","Conclusion | The First Clinical Signal Will Decide Whether AnBogen Is One Satellite—or a Constellation","References"],"references":[{"title":"[Starlink","source":"Technology]","date":"","url":"https://starlink.com/technology"},{"title":"[Merck","source":"2025 Form 10-K]","date":"","url":"https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf"},{"title":"[BeOne Medicines","source":"2025 Full-Year Results]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/exhibit991-q42025earningsr.htm"},{"title":"[AnBogen Therapeutics","source":"ABT-301 Triple Therapy Phase 1/2 Study]","date":"","url":"https://anbogen.com/en/news/cCCcD7dA6dcf"},{"title":"[Nature Medicine / PubMed","source":"Triple Therapy in MSS/pMMR Metastatic Colorectal Cancer]","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/38438735/"},{"title":"[AnBogen Therapeutics","source":"2026 AACR ABT-301 Research]","date":"","url":"https://anbogen.com/en/news/E6B4eB8309E6"},{"title":"[Credence Research","source":"Global Checkpoint Inhibitor-Refractory Cancer Drugs Market]","date":"","url":"https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market"},{"title":"[AnBogen Therapeutics","source":"Innovation Pipeline: ABT-500 Series, ABT-501, ABT-502, and ABT-505]","date":"","url":"https://mopsov.twse.com.tw/nas/STR/778420260429E001.pdf"}],"images":[{"alt":"Figure 1 | A “Starlink” for cancer immunotherapy: ABT-301 is designed to carry immune signaling into tumors that remain beyond the reach of current treatment.","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-01.png"},{"alt":"Figure 2 | ABT-301 is designed to reprogram the tumor microenvironment—making the tumor visible again and reactivating an immune response.","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-02.png"},{"alt":"Figure 3 | A sequential network of the ABT-301 triple therapy: reprogram the microenvironment, improve immune access, and release the immune brake.","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-03.png"},{"alt":"Figure 4 | From one satellite to a full constellation: ABT-301’s expansion blueprint across drugs, tumor types, and partners.","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-04.png"},{"alt":"Figure 5 | AnBogen’s capital-markets trajectory: from the first signal in 66 patients to a cross-tumor platform and a globally partnerable asset.","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-05.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-31）。AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy。https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-31-anbogen-immunotherapy-starlink.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}